Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients

Pharmacogenomics

Volumn 14, Issue 16, 2013, Pages 1991-1998

  Scartozzi, Mario ^a   Giampieri, Riccardo ^a   Loretelli, Cristian ^a   Bittoni, Alessandro ^a   Mandolesi, Alessandra ^a   Faloppi, Luca ^a   Bianconi, Maristella ^a   Prete, Michela Del ^a   Andrikou, Kalliopi ^a   Bearzi, Italo ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

cancer; chemotherapy; gastric; genotype; polymorphisms; VEGF

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; FLUOROURACIL; OXALIPLATIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLT1 GENE; FLT4 GENE; GENOTYPE; HUMAN; KDR GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TUMOR VASCULARIZATION; VEGF A GENE; VEGF C GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; STOMACH NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84889059175     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.185     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics. CA Cancer J. Clin. 60, 277-300 (2010).
2. Scartozzi M, Pistelli M, Bittoni A et al. Novel perspectives for the treatment of gastric cancer: from a global approach to a personalised strategy. Curr. Oncol. Rep. 12, 175-185 (2010).
3. Cunninhgam D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358, 36-46 (2008).
4. Yancopoule GD, Davis S, Gale NW et al. Vascular specific growth factors and blood vessel formation. Nature 407, 242-248 (2000).
5. Carmeliet P, Jain RK. Angiogenesis in cancer and other disease. Nature 407, 249-257 (2000).
6. Gluz O, Wild P, Liedtke C et al. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial. Breast Cancer Res. Treat. 126, 643-651 (2011).
7. Takahashi Y, Clearly KR, Mai M et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal type gastric cancer. Clin. Cancer Res. 2, 1679-1684 (1996).
8. Kitadai Y. Angiogenesis and lymphangiogenesis of gastric cancer. J. Oncology 2010, 1-8 (2010).
9. Zhang W, He X, Ma Y et al. Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis and poor prognosis in gastric cancer patients. Hum. Pathol. 42, 1275-1282 (2011).
10. Peng L, Zhan P, Zhou Y et al. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol. Biol. Rep. 39, 9473-9484 (2012).
11. Wang X, Chen X, Fang J, Yang C. Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int. J. Clin. Exp. Pathol. 6, 586-597 (2013).
12. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004).
13. Brown LM, Cowen RL, Debray C et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecules approaches targeting hypoxia inducible factor-1. Mol. Pharmacol. 69, 411-418 (2006).
14. van der Veldt AM, Lubberink M, Bahce I et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21, 82-91 (2012).
15. Siddiqui GK, Maclean AB, Elmasry K et al. Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer. Angiogenesis 14, 155-161 (2011).
16. Moeller BJ, Cao Y, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals and stress granules. Cancer Cell 5, 429-441 (2004).
17. Roberts DL, Williams KJ, Cowen RL et al. Contribution of HIF-I and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells. Br. J. Cancer 101, 1290-1297 (2009).
18. Tsuchida R, Das B, Yeger H et al. Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signalling. Oncogene 27, 3923-3934 (2008).
19. Gerger A, El-Khoueiry A, Zhang W et al. Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin. Cancer Res. 17, 5783-5792 (2011).
20. Scartozzi M, Bianconi M, Faloppi L et al. VEGF-And VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. Br. J. Cancer 108, 1126-1132 (2013).
21. Hansen TF, Garm Spindler KL, Andersen RF et al. The predictive value of genetic variations in the vascular endothelial growth factor gene A in metastatic colorectal cancer. Pharmacogenomics J. 11, 53-60 (2011).
22. Chen MH, Tzeng CH, Chen PM et al. VEGF-406TC polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenomics J. 11, 227-236 (2010).
23. Formento JL, Etienne-Grimaldi MC, Francoual M et al. influence of the VEGF-A 936CT germinal polymorphism on tumoral VEGF expression in head and neck cancer. Pharmacogenomics 10, 1277-1283 (2009).
24. Hansen TF, Sorensen FB, Spindler KL et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch. 456, 251-260 (2010).
25. Tamura T, Kuwahara A, Yamamori M et al. VEGF-634 C/G genotype is predictive of long-term survival after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int. J. Med. Sci. 9, 833-837 (2012).
26. Kim JG, Sohn SK, Chae YS et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with gastric cancer. Ann. Oncol. 18, 1030-1036 (2007).
27. Ruggiero D, Dalmasso C, Nutile T et al. Genetics of VEGF serum variation in human isolated populations of Cilento: importance of VEGF polymorphisms. PLoS ONE 6, e16982 (2011).
28. Oh SY, Kwon HC, Kim SH et al. The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 13, 43-50 (2013).
29. Hansen TF, Garm Spindler KL, Andersen RF et al. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J. 11, 53-60 (2011).
30. Chen MH, Tzeng CH, Chen PM et al. VEGF-460T-C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma. Pharmacogenomics J. 11, 227-236 (2011).